US biotech faces internal split over reliance on Chinese-developed drug candidates

Ed Silverman's Pharmalittle column notes that US biotech firms are wrestling with how to treat Chinese partners, with some seeing them as collaborators and others as competitors.

The column highlights a growing schism as both fledgling startups and large pharmaceutical companies increasingly depend on drug candidates discovered or developed in China, filling their pipelines with potential blockbusters.

This reliance is creating tension within the industry and raises strategic questions about supply, intellectual property and future growth, especially as recent setbacks such as a Regeneron trial failure add pressure.